arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

SAB Biotherapeutics, Inc.

SABS Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$2.84
▲ +0.7% Today
as of Oct 23, 16:06 ET
Last 30 days -17.92% Sep 14 → Oct 23
$2.41 $2.70 $3.00 $3.30 $3.59 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.83
High
$3.08
Low
$2.83
Volume
$708,897
Avg Vol
$567,741
Mkt Cap
$278M
P/E (TTM)
—
Beta
—
52w High
$5.15
52w Low
$2.44
Div Yield
—
Shares Out
$83M

Recent Press Releases & News last 60 days · 6 items

Oct 14 · 12:30 PR GlobeNewswire
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
Oct 13 · 13:17 MT Newswires
SAB Biotherapeutics Says SAB-142 Receives FDA Fast Track Designation in Type 1 Diabetes
Oct 13 · 12:30 PR GlobeNewswire
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
▸ Show all 6 press releases & news Free account →

SABS earnings at a glance

The options market is pricing a move of about ±18.8% after the report, a range of roughly $2.31 to $3.37 from today's $2.84. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±3.4% on average; after the most recent report on May 12, 2026 it moved -2.7%. That means options currently expect more movement than SABS has typically delivered. SABS beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 142%. The share price of $2.84 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.44
$5.15
15% of range
Avg surprise (last 4)
+0.1%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
142%
EM ±18.8% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.46$-0.84$-0.23$0.39$1.00 Actual $-1.46Actual $-1.36Actual $-0.97Actual $-0.54Actual $-0.79Actual $-1.12Actual $-0.56Est $1.00Actual $-1.09Est $-0.82Actual $-0.21Est $-0.59Actual $-0.35Est $-0.20Actual $-0.28 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-22M$-5M$13M$30M$48M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.28 — — — — financials
Tue May 12, 2026Mar/2026 $-0.35 $-0.20 -75.0% +37.5% -2.7% earnings
Fri Nov 14, 2025Sep/2025 $-0.21 $-0.59 +64.4% — — earnings
Thu Aug 7, 2025Jun/2025 $-1.09 $-0.82 -32.9% — — earnings
Fri May 9, 2025Mar/2025 $-0.56 $1.00 +44.0% — +4.1% earnings
Mon Sep 30, 2024Sep 2024 $-1.12 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.79 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.54 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.97 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.36 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.46 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-23M$-20M—$-13M$-10M$-11M—$-11M
Net income$-22M$-19M—$45M$-10M$-5M—$-10M
EPS (diluted)$-0.28$-0.35—$-0.21$-1.09$-0.56—$-1.12

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$8M$21M$11M$29M$4M$6M$9M$9M
Inventory————————
Total current assets$108M$113M$101M$113M$9M$16M$24M$33M
Total assets$238M$248M$173M$183M$30M$38M$44M$54M
Long-term debt————————
Total liabilities$23M$21M$21M$18M$18M$17M$18M$17M
Total equity$215M$227M$151M$165M$12M$21M$26M$37M

Implied volatility — last 90 days

24%405%787%1169%1550% Jun 15 — IV 347% · EM ±25.1%Jun 16 — IV 1107% · EM ±65.4%Jun 17 — IV 1551% · EM ±64.8%Jun 19 — IV 85% · EM ±18.8%Jun 22 — IV 82% · EM ±17.2%Jun 23 — IV 142% · EM ±29.1%Jun 24 — IV 153% · EM ±30.6%Jun 25 — IV 224% · EM ±43.9%Jun 26 — IV 165% · EM ±31.6%Jun 29 — IV 217% · EM ±38.5%Jun 30 — IV 424% · EM ±73.1%Jul 01 — IV 162% · EM ±27.1%Jul 02 — IV 79% · EM ±12.8%Jul 03 — IV 82% · EM ±12.8%Jul 06 — IV 276% · EM ±38.3%Jul 07 — IV 315% · EM ±41.7%Jul 08 — IV 381% · EM ±47.7%Jul 09 — IV 139% · EM ±16.4%Jul 13 — IV 417% · EM ±34.9%Jul 16 — IV 747% · EM ±31.2%Jul 20 — IV 24% · EM ±5.7%Jul 21 — IV 201% · EM ±46.7%Jul 22 — IV 360% · EM ±82.4%Jul 23 — IV 391% · EM ±88.0%Aug 06 — IV 168% · EM ±27.1%Aug 07 — IV 90% · EM ±14.1%Sep 10 — IV 309% · EM ±36.5%Sep 14 — IV 900% · EM ±75.1%Sep 16 — IV 1274% · EM ±75.2%Sep 17 — IV 718% · EM ±30.0%Sep 22 — IV 168% · EM ±34.3%Sep 23 — IV 147% · EM ±29.5%Sep 24 — IV 145% · EM ±28.4%Sep 25 — IV 135% · EM ±25.8%Sep 28 — IV 158% · EM ±28.0%Sep 29 — IV 153% · EM ±26.4%Sep 30 — IV 161% · EM ±26.8%Oct 01 — IV 40% · EM ±6.5%Oct 02 — IV 118% · EM ±18.5%Oct 06 — IV 142% · EM ±18.8%

Sector peers

XFOR
X4 Pharmaceuticals, Inc.
$279M $3.24+7.6%
FATE
Fate Therapeutics, Inc.
$276M $2.11+1.9%
LXEO
Lexeo Therapeutics, Inc.
$272M $2.80-6.7%
IKT
Inhibikase Therapeutics, Inc.
$269M $1.59-4.2%
IPSC
Century Therapeutics, Inc.
$292M $1.46-9.3%
SRZN
Surrozen, Inc.
$296M $25.48+0.6%

SABS earnings FAQ

What is SABS's expected move for earnings?

Options currently price a move of about ±18.8%, or $0.53 per share either way from $2.84.

How does SABS stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.4%, up 1 times and down 1 times.

What is SABS's implied volatility?

SABS's at-the-money implied volatility is about 142% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in